{
    "ticker": "BIVI",
    "name": "BioVie Inc.",
    "description": "BioVie Inc. is a biotechnology company focused on developing innovative therapies for liver disease and other neurological disorders. Founded in 2015, BioVie is committed to improving the lives of patients through cutting-edge research and development. The company's lead product candidate, NE3107, is being investigated for its potential to treat Alzheimer's disease, with a unique mechanism of action targeting insulin resistance and inflammation, crucial factors in neurodegeneration. BioVie is also advancing therapies for conditions such as ascites and hepatic encephalopathy, which are severe complications resulting from liver dysfunction. By leveraging its proprietary drug development platform and a team of experienced scientists and healthcare professionals, BioVie aims to bring novel treatments to market that address significant unmet medical needs. The company\u2019s mission extends to enhancing patient quality of life and providing effective solutions for chronic and debilitating diseases.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Los Angeles, California, USA",
    "founded": "2015",
    "website": "https://www.biovieinc.com",
    "ceo": "David L. Lichtenstein",
    "social_media": {
        "twitter": "https://twitter.com/BioVieInc",
        "linkedin": "https://www.linkedin.com/company/biovie-inc/"
    },
    "investor_relations": "https://www.biovieinc.com/investors",
    "key_executives": [
        {
            "name": "David L. Lichtenstein",
            "position": "CEO"
        },
        {
            "name": "Ryan S. Pappas",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "NE3107"
            ]
        }
    ],
    "seo": {
        "meta_title": "BioVie Inc. | Innovative Therapies for Liver Disease and Neurological Disorders",
        "meta_description": "Explore BioVie Inc., a biotechnology company dedicated to developing novel therapies for liver disease and neurological disorders. Learn about our innovative research and product candidates.",
        "keywords": [
            "BioVie",
            "Biotechnology",
            "Liver Disease",
            "Neurological Disorders",
            "NE3107"
        ]
    },
    "faq": [
        {
            "question": "What does BioVie focus on?",
            "answer": "BioVie focuses on developing innovative therapies for liver disease and neurological disorders."
        },
        {
            "question": "Who is the CEO of BioVie?",
            "answer": "David L. Lichtenstein is the CEO of BioVie Inc."
        },
        {
            "question": "Where is BioVie headquartered?",
            "answer": "BioVie is headquartered in Los Angeles, California, USA."
        },
        {
            "question": "What is BioVie's lead product candidate?",
            "answer": "BioVie's lead product candidate is NE3107, aimed at treating Alzheimer's disease."
        },
        {
            "question": "When was BioVie founded?",
            "answer": "BioVie was founded in 2015."
        }
    ],
    "competitors": [
        "ADMS",
        "SGEN",
        "FOLD"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "NVDA",
        "VRTX"
    ]
}